810 related articles for article (PubMed ID: 36569854)
1. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
Huang IH; Chung WH; Wu PC; Chen CB
Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
[TBL] [Abstract][Full Text] [Related]
2. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
Nakashima C; Yanagihara S; Otsuka A
Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171
[TBL] [Abstract][Full Text] [Related]
3. The role of Janus kinase signaling in the pathology of atopic dermatitis.
Guttman-Yassky E; Irvine AD; Brunner PM; Kim BS; Boguniewicz M; Parmentier J; Platt AM; Kabashima K
J Allergy Clin Immunol; 2023 Dec; 152(6):1394-1404. PubMed ID: 37536511
[TBL] [Abstract][Full Text] [Related]
4. Potential Natural Biomolecules Targeting JAK/STAT/SOCS Signaling in the Management of Atopic Dermatitis.
Kopalli SR; Annamneedi VP; Koppula S
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889539
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
Front Immunol; 2020; 11():620098. PubMed ID: 33658996
[TBL] [Abstract][Full Text] [Related]
7. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Garcia-Melendo C; Cubiró X; Puig L
Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
[TBL] [Abstract][Full Text] [Related]
8. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
Wood H; Chandler A; Nezamololama N; Papp K; Gooderham MJ
Int J Dermatol; 2022 Jun; 61(6):746-754. PubMed ID: 34423443
[TBL] [Abstract][Full Text] [Related]
9. Emerging trends in clinical research on Janus kinase inhibitors for atopic dermatitis treatment.
Shih PY; Li CJ; Yong SB
Int Immunopharmacol; 2023 Nov; 124(Pt B):111029. PubMed ID: 37820425
[TBL] [Abstract][Full Text] [Related]
10. Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives.
Munera-Campos M; Carrascosa JM
Actas Dermosifiliogr; 2023 Sep; 114(8):680-707. PubMed ID: 37105270
[TBL] [Abstract][Full Text] [Related]
11. English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis.
Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M;
J Dermatol; 2023 Jan; 50(1):e1-e19. PubMed ID: 36412059
[TBL] [Abstract][Full Text] [Related]
12. Abrocitinib for the treatment of atopic dermatitis.
Crowley EL; Nezamololama N; Papp K; Gooderham MJ
Expert Rev Clin Immunol; 2020 Oct; 16(10):955-962. PubMed ID: 32969750
[TBL] [Abstract][Full Text] [Related]
13. Innovation in Atopic Dermatitis: From Pathogenesis to Treatment.
Munera-Campos M; Carrascosa JM
Actas Dermosifiliogr (Engl Ed); 2020 Apr; 111(3):205-221. PubMed ID: 31964499
[TBL] [Abstract][Full Text] [Related]
14. The suitability of treating atopic dermatitis with Janus kinase inhibitors.
Narla S; Silverberg JI
Expert Rev Clin Immunol; 2022 May; 18(5):439-459. PubMed ID: 35377276
[TBL] [Abstract][Full Text] [Related]
15. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
16. JAK/STAT Inhibition Normalizes Lipid Composition in 3D Human Epidermal Equivalents Challenged with Th2 Cytokines.
Flori E; Cavallo A; Mosca S; Kovacs D; Cota C; Zaccarini M; Di Nardo A; Bottillo G; Maiellaro M; Camera E; Cardinali G
Cells; 2024 Apr; 13(9):. PubMed ID: 38727296
[TBL] [Abstract][Full Text] [Related]
17. The JAK/STAT Pathway and Its Selective Inhibition in the Treatment of Atopic Dermatitis: A Systematic Review.
Tsiogka A; Kyriazopoulou M; Kontochristopoulos G; Nicolaidou E; Stratigos A; Rigopoulos D; Gregoriou S
J Clin Med; 2022 Jul; 11(15):. PubMed ID: 35956047
[TBL] [Abstract][Full Text] [Related]
18. Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies.
Kogame T; Egawa G; Kabashima K
Immunol Med; 2023 Sep; 46(3):112-120. PubMed ID: 37254967
[TBL] [Abstract][Full Text] [Related]
19. JAK Inhibitors for Atopic Dermatitis: An Update.
He H; Guttman-Yassky E
Am J Clin Dermatol; 2019 Apr; 20(2):181-192. PubMed ID: 30536048
[TBL] [Abstract][Full Text] [Related]
20. Oral Janus kinase inhibitors for atopic dermatitis.
Mikhaylov D; Ungar B; Renert-Yuval Y; Guttman-Yassky E
Ann Allergy Asthma Immunol; 2023 May; 130(5):577-592. PubMed ID: 36736457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
